Skip to content

    Skin Problems & Treatments Health Center

    Font Size
    A
    A
    A

    Orbactiv Approved for Drug-Resistant Skin Infections

    Third such antibiotic sanctioned this year

    WebMD News from HealthDay

    By Scott Roberts

    HealthDay Reporter

    THURSDAY, Aug. 7, 2014 (HealthDay News) -- The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.

    The drug is sanctioned to treat methicillin-resistant Staphylococcus aureus (MRSA) and other acute bacterial skin infections. It's the third such drug approved in 2014, following May approval of Dalvance (dalbavancin) and June approval of Sivextro (tedizolid), the FDA said.

    Orbactiv's safety and effectiveness were evaluated in two clinical studies involving almost 2,000 adults. The most common side effects included headache, nausea, vomiting, skin abscesses on the arms and legs, and diarrhea.

    The drug's label will include a boxed warning that it could interact with the blood-thinning medication warfarin, the agency said.

    Orbactiv is marketed by The Medicines Company, based in Parsippany, N.J.

    Today on WebMD

    chafing
    Pictures and symptoms of the red, scaly rash.
    woman with dyed dark hair
    What it says about your health.
     
    woman with cleaning products
    Top causes of the itch that rashes.
    atopic dermatitus
    Identify and treat common skin problems.
     
    itchy skin
    Article
    shingles rash on skin
    Article
     
    woman with skin tag
    Quiz
    Woman washing face
    Video
     
    woman washing her hair in sink
    Video
    close up of womans bare neck
    Tools
     
    Feet
    Slideshow
    woman with face cream
    Quiz